Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share guidance of 7.750-8.250 for the period, compared to the consensus earnings per share estimate of 8.010. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion.
Wall Street Analysts Forecast Growth
A number of research firms have commented on HALO. Wall Street Zen downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. Finally, HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $79.11.
Check Out Our Latest Stock Analysis on HALO
Halozyme Therapeutics Price Performance
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, research analysts predict that Halozyme Therapeutics will post 7.68 EPS for the current fiscal year.
Insider Transactions at Halozyme Therapeutics
In other news, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $63.48, for a total value of $103,155.00. Following the transaction, the director owned 38,498 shares of the company’s stock, valued at $2,443,853.04. The trade was a 4.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the sale, the chief operating officer owned 14,366 shares in the company, valued at $974,014.80. This represents a 58.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 90,482 shares of company stock valued at $6,073,942 in the last quarter. Insiders own 2.50% of the company’s stock.
Institutional Investors Weigh In On Halozyme Therapeutics
A number of large investors have recently made changes to their positions in HALO. Empowered Funds LLC acquired a new stake in shares of Halozyme Therapeutics during the first quarter valued at approximately $755,000. Acadian Asset Management LLC acquired a new stake in shares of Halozyme Therapeutics during the first quarter valued at approximately $195,000. Hsbc Holdings PLC raised its holdings in shares of Halozyme Therapeutics by 117.1% during the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 5,448 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares during the period. Finally, Baird Financial Group Inc. raised its holdings in shares of Halozyme Therapeutics by 6.2% during the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 650 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Read More
- Five stocks we like better than Halozyme Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
